A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Astellas Pharma Inc
Alexion Pharmaceuticals, Inc.
Novartis
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Celgene
Novartis
Celgene
BioNTech SE
EMD Serono
Celgene
Zhejiang Teruisi Pharmaceutical Inc.
AstraZeneca
Eli Lilly and Company
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Bayer
Janssen Scientific Affairs, LLC
Merck Sharp & Dohme LLC
Astex Pharmaceuticals, Inc.
Ipsen
AstraZeneca
Pfizer
Genentech, Inc.
US Oncology Research
Innovent Biologics (Suzhou) Co. Ltd.
Eli Lilly and Company
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Hoffmann-La Roche
Hoffmann-La Roche
Pfizer
Janssen Research & Development, LLC
Sanofi
Presage Biosciences
Sanofi
Sanofi
Sanofi
Sanofi
GlaxoSmithKline
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.